Brentuximab vedotin (solution)
Based on 1 publication(s) in Google Scholar
Brentuximab vedotin (solution) (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). The antibody portion is Brentuximab (HY-P99151), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Brentuximab vedotin (solution) inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin (solution) can be used for the research of relapsed and refractory Hodgkin lymphoma.
For research use only. We do not sell to patients.
- Purity : 99.73%
- CAS No.: 914088-09-8
- Molecular Weight:153000 (average)
-
Storage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-138298
Trastuzumab deruxtecan (solution)HER2 ADC -
HY-P99016B
Enfortumab vedotin-ejfv (solution)Nectin-4 ADC -
HY-152963
Tisotumab vedotinAntibody-Drug Conjugate -
HY-138298A
Trastuzumab deruxtecanHER2 ADC -
HY-P9921A
Trastuzumab emtansine (solution)Antibody-Drug Conjugate -
HY-132253
Polatuzumab vedotinMicrotubule Inhibitor -
HY-132254A
Sacituzumab govitecan (solution)Trop-2 ADC -
HY-P3239
Belantamab mafodotinAnti-BCMA ADC -
HY-P9985
Disitamab vedotinHER2-Directed ADC -
HY-132254
Sacituzumab govitecanTrop-2 ADC -
HY-P9921
Trastuzumab emtansineAntibody-drug Conjugate -
HY-P99016A
Enfortumab vedotin-ejfvNectin-4 ADC
Publications Citing Use of MedChemExpress (MCE) Brentuximab vedotin (solution)
More
Biological Activity
Description
In Vitro
Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 914088-09-8
-
Appearance Liquid
-
Molecular Weight 153000 (average)
-
Color Colorless to light yellow
-
SMILES
[Brentuximab vedotin (solution)]
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Publications (1)
-
Journal Impact Factor
-
Most Recent
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Shea L, Mehta-Shah N. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. Curr Hematol Malig Rep. 2020 Feb;15(1):9-19. [Content Brief]
[2]. Francisco JA, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Brentuximab vedotin (solution) Related Classifications
HY-P99107A Related Classifications
Powered by Bioz